Patents by Inventor Brian Jay Druker

Brian Jay Druker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110129852
    Abstract: The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.
    Type: Application
    Filed: July 12, 2010
    Publication date: June 2, 2011
    Inventors: Christophe Barthe, Pascale Cony-Makhoul, Amie Corbin, Sven De Vos, Brian Jay Druker, Harald Gschaidmeier, Michael Hallek, Andreas Hochhaus, Dieter Hoelzer, Wolf-Karsten Hofmann, Phillip Koeffler, Sebastian Kreil, Francois-Xavier Mahon, Martin Müller, Oliver Gerhard Ottmann, Markus Warmuth
  • Publication number: 20100021920
    Abstract: The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of
    Type: Application
    Filed: August 21, 2009
    Publication date: January 28, 2010
    Inventors: Christophe Barthe, Susan Branford, Amie Corbin, Brian Jay Druker, Justus Duyster, Andreas Hochhaus, Timothy Hughes, Sebastian Kreil, Thlbaut Leguay, Francois-Xavier Mahon, Gèrald Marit, Martin Müller, Christian Peschel, Claude Preudhomme, Catherine Roche Lestienne, Zbigniew Rudzki
  • Publication number: 20100021921
    Abstract: The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of
    Type: Application
    Filed: August 21, 2009
    Publication date: January 28, 2010
    Inventors: Christophe Barthe, Susan Branford, Amie Corbin, Brian Jay Druker, Justus Duyster, Andreas Hochhaus, Timothy Hughes, Sebastian Kreil, Thibaut Leguay, Francois-Xavier Mahon, Gerald Marit, Martin Muller, Christian Peschel, Claude Preudhomme, Catherine Roche Lestienne, Zbigniew Rudzki
  • Publication number: 20090191606
    Abstract: The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1 -ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.
    Type: Application
    Filed: December 17, 2008
    Publication date: July 30, 2009
    Inventors: Christophe Barthe, Pascale Cony-Makhoul, Amie Corbin, Sven De Vos, Brian Jay Druker, Harald Gschaidmeier, Michael Hallek, Andreas Hochhaus, Dieter Hoelzer, Wolf-Karsten Hofmann, Phillip Koeffler, Sebastian Kreil, Francois-Xavier Mahon, Martin Muller, Oliver Gerhard Ottmann, Markus Warmuth
  • Publication number: 20090117641
    Abstract: The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of
    Type: Application
    Filed: June 30, 2008
    Publication date: May 7, 2009
    Inventors: Christophe Barthe, Susan Bradford, Amie Corbin, Brian Jay Druker, Justus Duyster, Andreas Hochhaus, Timothy Hughes, Sebastian Kreil, Thibaut Leguay, Francios-Xavier Mahon, Gerald Marit, Martin Muller, Christian Peschel, Claude Preudhomme, Catherine Roche Lestienne, Zbigniew Rudzki
  • Patent number: 6958335
    Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: October 25, 2005
    Assignees: Novartis AG, Dana-Farber Cancer Institute, Inc., Oregon Health & Science University
    Inventors: Elisabeth Buchdunger, Renaud Capdeville, George Daniel Demetri, Sasa Dimitrijevic, Brian Jay Druker, Jonathan A. Fletcher, Michael C. Heinrich, Heikki Joensuu, Sandra Leta Silberman, David Tuveson
  • Publication number: 20040023976
    Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula (I) or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.
    Type: Application
    Filed: August 11, 2003
    Publication date: February 5, 2004
    Inventors: Elisabeth Buchdunger, Renaud Capdeville, George Daniel Demetri, Sasa Dimitrijevic, Brian Jay Druker, Jonathan A. Fletcher, Michael C. Heinrich, Heikki Joensuu, Sandra Leta Silberman, David Tuveson
  • Publication number: 20030170851
    Abstract: The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.
    Type: Application
    Filed: October 3, 2002
    Publication date: September 11, 2003
    Inventors: Christophe Barthe, Pascale Cony-Makhoul, Amie Corbin, Sven De Vos, Brian Jay Druker, Harald Gschaidmeier, Michael Hallek, Andreas Hochhaus, Dieter Hoelzer, Wolf-Karsten Hofmann, Phillip Koeffler, Sebastian Kreil, Francois-Xavier Mahon, Martin Muller, Oliver Gerhard Ottmann, Markus Warmuth